Novacyt (ALNOV.PA) Stock Price
Novacyt Price
Over the last 16 years Novacyt grew revenue by 28.9% annually, reaching 19.63 M GBP. For Novacyt, the net margin of -212.7% is down versus 47.8% a few years ago. The consensus 12-month price target for Novacyt is 3.58 GBP, about 72,813.8% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 79% above its 52-week low.
Novacyt stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Novacyt over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Novacyt stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Novacyt's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Novacyt Price |
|---|---|
| 8/28/2026 | 0.00 GBP |
| 8/27/2026 | 0.00 GBP |
| 8/26/2026 | 0.01 GBP |
| 8/25/2026 | 0.01 GBP |
| 8/24/2026 | 0.01 GBP |
| 8/21/2026 | 0.01 GBP |
| 8/20/2026 | 0.00 GBP |
| 8/19/2026 | 0.01 GBP |
| 8/18/2026 | 0.01 GBP |
| 8/17/2026 | 0.01 GBP |
| 8/14/2026 | 0.01 GBP |
| 8/13/2026 | 0.01 GBP |
| 8/12/2026 | 0.01 GBP |
| 8/11/2026 | 0.00 GBP |
| 8/10/2026 | 0.00 GBP |
| 8/7/2026 | 0.00 GBP |
| 8/6/2026 | 0.00 GBP |
| 8/5/2026 | 0.00 GBP |
| 8/4/2026 | 0.00 GBP |
| 8/3/2026 | 0.00 GBP |
| 7/31/2026 | 0.00 GBP |
| 7/30/2026 | 0.00 GBP |
| 7/29/2026 | 0.00 GBP |
| 7/28/2026 | 0.00 GBP |
| 7/27/2026 | 0.00 GBP |
| 7/24/2026 | 0.00 GBP |
| 7/23/2026 | 0.00 GBP |
| 7/22/2026 | 0.00 GBP |
| 7/21/2026 | 0.00 GBP |
| 7/20/2026 | 0.00 GBP |
Novacyt Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Novacyt Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM GBP |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM GBP |
| EBITM GBP |
| EBIT MARGIN% |
| NET INCOMEM GBP |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 1.00 | 4.00 | 8.00 | 9.00 | 11.00 | 12.00 | 11.00 | 277.00 | 92.00 | 21.00 | 10.00 | 19.00 | 19.00 | 26.00 | 30.00 |
| – | – | 300.00 | 100.00 | 12.50 | 22.22 | 9.09 | -8.33 | 2,418.18 | -66.79 | -77.17 | -52.38 | 90.00 | – | 36.84 | 15.38 |
| – | 3,200.00 | 25.00 | 50.00 | 55.56 | 54.55 | 58.33 | 63.64 | 76.17 | 30.43 | 23.81 | 30.00 | 168.42 | 168.42 | 168.42 | 168.42 |
| 32.00 | 32.00 | 1.00 | 4.00 | 5.00 | 6.00 | 7.00 | 7.00 | 211.00 | 28.00 | 5.00 | 3.00 | 32.00 | 32.00 | 43.79 | 50.53 |
| – | -1.00 | -3.00 | -3.00 | -3.00 | -1.00 | – | -1.00 | 174.00 | 1.00 | -14.00 | -14.00 | -14.00 | -12.00 | -16.00 | -18.00 |
| – | -100.00 | -75.00 | -37.50 | -33.33 | -9.09 | – | -9.09 | 62.82 | 1.09 | -66.67 | -140.00 | -73.68 | -63.16 | -61.54 | -60.00 |
| – | -1.00 | -3.00 | -13.00 | -4.00 | -4.00 | -4.00 | -5.00 | 132.00 | -9.00 | -25.00 | -28.00 | -41.00 | -10.00 | -8.00 | -4.00 |
| – | – | 200.00 | 333.33 | -69.23 | – | – | 25.00 | -2,740.00 | -106.82 | 177.78 | 12.00 | 46.43 | -75.61 | -20.00 | -50.00 |
| 2.43 | 2.93 | 4.44 | 6.79 | 12.09 | 23.08 | 37.66 | 45.73 | 68.19 | 70.63 | 70.63 | 70.63 | 70.63 | 70.63 | 70.63 | 70.63 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Novacyt generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Novacyt retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Novacyt's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Novacyt has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Novacyt's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Novacyt stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Novacyt Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Novacyt business model & stock analysis
Novacyt SWOT Analysis
Strengths
Novacyt SA has a strong global presence, with operations in several countries and a diverse customer base.
The company has a strong brand reputation and a track record of developing high-quality diagnostic products.
Novacyt SA has a skilled and experienced workforce, which enables it to innovate and adapt quickly to changing market dynamics.
Weaknesses
One of the weaknesses of Novacyt SA is its dependence on a few key customers, which exposes it to the risk of losing significant revenue if any of those customers switch to competitors.
The company may face challenges in maintaining regulatory compliance across different markets due to variations in regulations.
Novacyt SA operates in a highly competitive industry, which can put pressure on pricing and profit margins.
Opportunities
There is a growing demand for diagnostic products and services globally, presenting an opportunity for Novacyt SA to expand its market share.
The company can explore strategic partnerships or acquisitions to enhance its product portfolio and reach new markets.
Advancements in technology and increasing awareness of preventive healthcare can create opportunities for Novacyt SA to develop innovative diagnostic solutions.
Threats
The COVID-19 pandemic has resulted in increased competition in the diagnostic testing market, which can pose a threat to Novacyt SA's market position.
Supply chain disruptions or shortages of raw materials can impact the company's production and delivery capabilities.
Changes in healthcare policies or reimbursement rates can affect the demand and pricing of Novacyt SA's products.
Novacyt Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Novacyt historical P/E ratio, EBIT multiple, and P/S ratio
Novacyt annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Novacyt shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Novacyt forecasts and price targets in September 2026
Analyst Price Targets 2026Novacyt Earnings Calls
Novacyt Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/16/2017 | -0.09GBP | - | 7.10 MGBP | - | 2017 Q2 |
| 4/27/2017 | 0.06GBP | - | 6.09 MGBP | - | 2016 Q4 |
Novacyt shareholder structure
| % | Name |
|---|---|
0.04811% | |
0.01291% |
Novacyt Beneficial Ownership Filings (SEC 13D/G)
Novacyt Executives and Management Board
10 members · avg. age 56 · 40 % women
Mr. Lyn Rees (50)
Chief Executive Officer, Executive Director · since 2023
108,008.00 GBP
Management
Mr. Steve Gibson (42)
Chief Financial Officer, Company Secretary, Director
Mr. Peter Coyne
Chief Operating Officer
Dr. Joanne Mason (50)
Chief Scientific Officer, Executive Director · since 2024
Ms. Maria Watters
Chief Commercial Officer
Board of Directors
Ms. Juliet Thompson
Independent Non-Executive Director
Mr. Jean-Pierre Crinelli (74)
Independent Non-Executive Director · since 2021
Dr. John Brown
Non-Executive Chairman of the Board · since 2023
Ms. Wendy Cox
Director - Human Resources
Dr. Ian Gilham (65)
Non-Executive Director
Frequently asked questions about Novacyt
Novacyt SA's business model revolves around the development, manufacturing, and distribution of innovative diagnostic solutions. As a global leader in clinical diagnostics, Novacyt focuses on providing fast, accurate, and easy-to-use testing solutions for infectious diseases, primarily respiratory infections. The company's broad range of products includes molecular and protein-based diagnostic tests, which are utilized by healthcare professionals worldwide to identify and monitor various diseases. Novacyt's business model is built on continuous innovation, strategic partnerships, and a commitment to delivering high-quality diagnostic solutions to improve patient outcomes. With its comprehensive portfolio and strong market presence, Novacyt SA is dedicated to advancing the field of diagnostics and meeting the evolving needs of the healthcare industry.
Novacyt SA primarily operates in the healthcare and biotechnology industries.
The main competitors of Novacyt SA in the market include companies such as PerkinElmer, Inc., Quidel Corporation, and Abbott Laboratories.
Novacyt SA is a renowned biotechnology company specializing in clinical diagnostics. Founded in 2006, Novacyt has since emerged as a global leader in the field. With a strong focus on research and development, the company has developed innovative solutions for the rapid detection and diagnosis of infectious diseases and various types of cancer. Novacyt's cutting-edge technology has gained recognition worldwide, enabling accurate and timely results. Through strategic partnerships and collaborations, Novacyt continues to expand its product portfolio and enhance its presence in international markets. With a commitment to improving global healthcare, Novacyt SA remains at the forefront of innovative diagnostics solutions.
Novacyt SA has achieved several significant milestones. Notably, the company developed and launched its NOVAprep® liquid-based cytology system, providing an innovative solution for cervical cancer screening. Furthermore, Novacyt SA successfully acquired Primerdesign Ltd, a molecular diagnostics company specializing in infectious diseases, expanding its product portfolio and market reach. The company also received Emergency Use Authorization from the US FDA for its COVID-19 testing kit, allowing for rapid and accurate diagnosis during the global pandemic. Novacyt SA's continuous commitment to innovation and strategic acquisitions has positioned it as a prominent player in the field of diagnostics and molecular testing.
Novacyt SA is primarily present in various countries and regions worldwide. As a global biotechnology company, Novacyt SA has established its presence in key markets such as Europe, including France, Germany, and the United Kingdom. Additionally, the company has expanded its operations into North America, with a strong focus on the United States. Novacyt SA also maintains a significant presence in other regions, including Asia, Latin America, and the Middle East. With its international reach, Novacyt SA is committed to serving the needs of customers and stakeholders across diverse geographies, contributing to its overall growth and success.
Novacyt SA is a leading international diagnostics company that prides itself on its commitment to high values and corporate philosophy. With a focus on innovation, Novacyt prioritizes providing accurate and reliable diagnostic solutions to improve global healthcare outcomes. The company's core values revolve around quality, integrity, and collaboration. Novacyt SA aims to meet the highest standards in every aspect of its operations, from research and development to manufacturing and customer support. By embracing a customer-centric approach and fostering partnerships, Novacyt SA strives to deliver impactful diagnostic solutions and contribute to the advancement of healthcare worldwide.
Analysts currently set an average price target of 3.58 GBP for the Novacyt stock (median: 3.58 GBP), implying +613.2 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Novacyt stock: 0 recommend buying, 2 holding and 5 selling. For 2026, analysts expect Novacyt to generate revenue of 26.50 M GBP and earnings per share of -0.13 GBP.
Converted at the current exchange rate, the Novacyt share trades at 0.01 EUR (0.00 GBP).
The Novacyt share (ALNOV.PA) is listed on 8 stock exchanges, including: Frankfurt (NYZ.F), München (NYZ.MU), Düsseldorf (NYZ.DU), London (NCYT.L), London (NCYT.L), Paris (ALNOV.PA).
Novacyt SA is a multinational company that offers innovative diagnostic products and services for clinical diagnostics, life science research, and biopharmaceuticals. The company specializes in the development, manufacturing, and marketing of products for the diagnostics of infectious diseases and cancer. The core business of Novacyt SA is the development and marketing of molecular diagnostic tests for a variety of infectious diseases and types of cancer. The tests are specifically used for in vitro diagnostics and are based on polymerase chain reaction (PCR) technology. The tests are designed for rapid and accurate diagnosis of infectious diseases such as Covid-19, influenza, HIV, hepatitis, and tuberculosis, as well as cancer types such as prostate cancer and lung cancer. Novacyt SA operates in two business areas: diagnostics and biopharma. In the diagnostics sector, the company develops and markets molecular diagnostic tests used for the diagnosis of infectious diseases and cancer. The products of the diagnostics business include the NOVAprep cytology supplement and the RUBIDIUM radionuclide. In the biopharma sector, Novacyt SA produces and markets recombinant proteins and antibodies for research and development of innovative therapeutics and vaccines. The products of the biopharma business include purified beta-lactamase, cystatin C, and CD20, essential components for the development of cancer therapeutics and vaccines. Novacyt SA is focused on strengthening its market position in the diagnostics and biopharma sectors through the expansion of its portfolio of diagnostic tests and the development of new products for biopharma research. Additionally, Novacyt SA continuously conducts research and development activities to bring future products for the diagnosis of infectious diseases and types of cancer to the market. Novacyt SA has a strong presence in the global market and operates in over 100 countries worldwide. The company is oriented towards collaborating with partners in Europe, the Middle East, Africa, and Asia to market its products and services in different regions across the world. Overall, Novacyt SA has structured its business model around two pillars: molecular diagnostic tests and biopharma products. The company specializes in the development of products for the diagnostics of infectious diseases and cancer and aims to expand its presence in the global market and broaden its portfolio of diagnostic tests and biopharma products.
The expected revenue of Novacyt is 26.50 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Novacyt is -8.86 M GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Novacyt is currently -0.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Novacyt stock.
The price-to-sales ratio (P/S) of Novacyt is currently 0.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Novacyt stock.
The Eulerpool Quality Score for Novacyt is 2/10.
The ISIN of Novacyt is FR0010397232. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Novacyt is A12CFH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Novacyt is ALNOV.PA. The ticker symbol is used to trade Novacyt shares on the stock exchange.
Novacyt paid dividends every year for the past 0 years.
Novacyt is assigned to the 'Health' sector.
The dividends of Novacyt are distributed in GBP.
Novacyt stock
Novacyt Peer Group
Novacyt Ticker
Novacyt FIGI
All fundamentals and in-depth analysis of Novacyt
Our stock analysis for Novacyt stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.